Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.66 |
| ▸ | CCNK | O75909 | 11/20 | 0.54 |
| ▸ | CDK12 | Q9NYV4 | 11/20 | 0.54 |
| ▸ | CDK7 | P50613 | 11/20 | 0.54 |
| ▸ | CCNH | P51946 | 10/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.54 |
| ▸ | CDK9 | P50750 | 9/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.54 |
| ▸ | CDK2 | P24941 | 8/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.54 |
| ▸ | MNAT1 | P51948 | 9/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
| ▸ | JUN | P05412 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613520 | 1.00 | RPS6KA5 (0.66) | RPS6KA5CCNKCDK12CDK7CCNH | |
| SCHEMBL20536984 | 0.86 | CDK2 (0.51) | RPS6KA5CCNKCDK12CDK7CCNH | |
| SCHEMBL17150733 | 0.85 | CDK5 (0.71) | CCNKCDK12CDK7CCNHCCNT1 | |
| SCHEMBL518282 | 0.85 | CDK5 (0.49) | RPS6KA5CLK1CDK5CDK5R1 | |
| SCHEMBL30957423 | 0.85 | CDK5 (0.49) | RPS6KA5CLK1CDK5CDK5R1 | |
| SCHEMBL23152046 | 0.85 | CLK1 (0.71) | RPS6KA5CCNKCDK12CCNT1CDK9 | |
| SCHEMBL19054825 | 0.85 | CCNK (0.54) | RPS6KA5CCNKCDK12CDK7CCNH | |
| SCHEMBL22510124 | 0.85 | CDK5 (0.56) | RPS6KA5CLK1CDK5CDK5R1 | |
| SCHEMBL517759 | 0.85 | CCNT1 (0.52) | RPS6KA5CCNKCDK12CCNT1CDK9 | |
| SCHEMBL517438 | 0.85 | JAK2 (0.55) | RPS6KA5CCNKCDK12CDK7CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260092051-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-02 | — | — | US | disclosed |
| US-12325698-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | HANMI PHARM. CO., LTD. (KR) | 2025-06-10 | — | — | US | disclosed |
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | ACEA Therapeutics, Inc. (US) | 2025-05-01 | — | — | US | disclosed |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-12-26 | — | — | US | disclosed |
| US-20240409609-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2024148210-A1 | CYCLIN-DEPENDENT KINASE 12 MODULATORS AND THERAPEUTIC USES THEREOF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | WO | disclosed |
| CN-112469715-B | Pyrimidine compound and pharmaceutical composition for preventing or treating cancer comprising the same | 韩美药品株式会社 | 2024-06-11 | — | — | CN | disclosed |
| US-20240182441-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-06 | — | — | US | disclosed |
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | Design Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2013-02-28 | — | — | US | disclosed |
| WO-2013014448-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2013-01-31 | — | — | WO | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | RPS6KA5 388/4885CCNK 2637/4885CDK12 2722/4885 |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | RPS6KA5 280/4885CCNK 194/4885CDK12 478/4885 |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | RPS6KA5 235/4885CCNK 139/4885CDK12 469/4885 |
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | MTPN, DMPK, MBNL1 | RPS6KA5 1257/4885CCNK 518/4885CDK12 1586/4885 |
| US-12325698-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | DPYD, TYMS, TYMP | RPS6KA5 1956/4885CCNK 179/4885CDK12 607/4885 |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | RPS6KA5 388/4885CCNK 2637/4885CDK12 2722/4885 |
| US-20240409609-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | EGFR, ERBB2, ERBB3 | RPS6KA5 721/4885CCNK 570/4885CDK12 260/4885 |
| US-20260092051-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | FLT3, FLT1, ADK | RPS6KA5 841/4885CCNK 283/4885CDK12 1172/4885 |
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | CHEK2, CDK2, CDK1 | RPS6KA5 122/4885CCNK 95/4885CDK12 170/4885 |
| US-20240182441-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | RPS6KA5 388/4885CCNK 2637/4885CDK12 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.